rF1V vaccine

The rF1V vaccine is a recombinant subunit plague vaccine designed to protect against infection by *Yersinia pestis*, the bacterium that causes plague. It consists of a fusion protein combining the F1 capsular antigen and the V virulence antigen from *Y. pestis*, produced in *Escherichia coli* and formulated with an aluminum-based adjuvant (Alhydrogel). The F1 component provides protection against bubonic plague, while the V component confers protection against pneumonic plague. The primary indication is for prophylaxis in adults aged 18 to 55 years at risk of exposure to aerosolized *Y. pestis* (e.g., as a biothreat agent). The U.S. Department of Defense has led its development; recent efforts involve Dynavax Technologies Corporation evaluating an improved formulation (rF1V-1018) using their CpG 1018 adjuvant to enhance immune response and reduce dosing requirements[2][3][6]. Clinical development has included Phase 2 trials[3][7].

Other names

recombinant F1-V plague vaccinerecombinant Yersinia pestis F1-V fusion protein vaccine